Answers are grounded in this paper and cite their sources.
Background: Aglaia simplicifolia, a species belonging to the family Meliaceae, is traditionally used in ethnomedicinal practices for various ailments. However, its hepatoprotective potential has not been comprehensively validated scientifically. Objective: This study aimed to evaluate the pharmacognostic characteristics, preliminary phytochemical composition, and in vitro hepatoprotective activity of the ethanolic leaf extract of A. simplicifolia against chemically induced hepatic injury. Methods: Dried leaves of A. simplicifolia were extracted with 95% ethanol using a Soxhlet apparatus. Pharmacognostic evaluation and Preliminary phytochemical screening was performed using standard qualitative tests. Hepatoprotective activity was evaluated in an isolated primary rat hepatocyte model. The cells were exposed to four hepatotoxic agents: diethylnitrosamine (DEN), cisplatin, thioacetamide (TAA), and rifampicin (RMP). Cell viability was determined using the Trypan blue exclusion method, with silymarin (100 µg/mL) as the reference standard. Results: In the evaluation we measured physicochemical parameters. Preliminary phytochemical screening showed that the extract contains alkaloids, flavonoids, steroids, glycosides, saponins, tannins and carbohydrates. In the hepatocyte cell viability assay I observed that the extract at 100 µg/mL improved cell viability in all four models. Cell viability was 73.09% for DEN 72.56% for cisplatin, 78.31% for TAA and 84.77% for RMP. For comparison silymarin produced cell viability of 81.14%, 78.31%, 83.06% and 84.60% in the models. In the rifampicin-induced hepatotoxicity model the extract gave a higher cell viability of 84.77%, than silymarin's 84.60%. Conclusion: The ethanolic leaf extract of A. simplicifolia showed in vitro hepatoprotective activities. These preliminary findings suggest that the extract may contain constituents with biological activity relevant to hepatic protection. Further studies, including bioassay-guided isolation, characterization of active constituents, and in vivo evaluation, are required to establish its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
N. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: